Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minutes
Jackson Center, Pennsylvania--(Newsfile Corp. - October 18, 2022) - Halberd Corporation (OTC Pink: HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria. The combined bacteria-antibody-nanoparticle cluster are then exposed to laser emissive energy. In lab testing, over 90% of each bacteria was eliminated in less than 20...
2022-10-18 8:00 AM EDT
Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum
Jackson Center, Pennsylvania--(Newsfile Corp. - October 12, 2022) - Halberd Corporation (OTC Pink: HALB) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions.Unlike Halberd's earlier successful experiments, which eliminated IL-6 from cerebrospinal fluid (CSF) through exposure to laser irradiation, this recent experiment used an engineered antibody with...
2022-10-12 8:00 AM EDT
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
Jackson Center, Pennsylvania--(Newsfile Corp. - September 27, 2022) - Halberd Corporation (OTC Pink: HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named "ExtendalifeTM". The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer's Disease and Cancer treatments using the combined patented and patent-pending technologies of the...
2022-09-27 8:00 AM EDT
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
Jackson Center, Pennsylvania--(Newsfile Corp. - August 23, 2022) - Halberd Corporation (OTC Pink: HALB) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death-1) is a T-Cell protein which can be used by tumor cells to fool the body's immune system into allowing the tumor to grow1. Halberd's extracorporeal process, operating on blood serum, can potentially be used to eliminate PD-1 and...
2022-08-23 8:00 AM EDT
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
Jackson Center, Pennsylvania--(Newsfile Corp. - August 4, 2022) - Halberd Corporation (OTC Pink: HALB) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd's research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer's Disease,...
2022-08-04 8:00 AM EDT
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
Jackson Center, Pennsylvania--(Newsfile Corp. - July 20, 2022) - Halberd Corporation (OTC Pink: HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel until such time as business opportunities arise and appropriately skilled...
2022-07-20 8:00 AM EDT
Halberd's Antibody Effective Against All 4 SARS-CoV-2 Mutations, Including Omicron
Jackson Center, Pennsylvania--(Newsfile Corp. - July 14, 2022) - Halberd Corporation (OTC Pink: HALB) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd's antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness of the commercial antibody was increased from 65% to 94%. This could lead to a treatment that is...
2022-07-14 8:00 AM EDT
Halberd Corporation Update, CEO Letter and 2022 Expectations
Jackson Center, Pennsylvania--(Newsfile Corp. - July 12, 2022) - Halberd Corporation (OTC Pink: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows:2Q ACHIEVEMENTSAdded an animal testing expert (DVM/PhD) to our list of scientific consultants to plan and execute extensive animal testing of Halberd's patented extracorporeal process for the...
2022-07-12 8:00 AM EDT
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
Jackson Center, Pennsylvania--(Newsfile Corp. - June 21, 2022) - Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC Pink: HALB) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd's technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments.The subgroup will be guided by Halberd's existing technical team members,...
2022-06-21 9:01 AM EDT
Halberd Corp. and Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
Jackson Center, Pennsylvania--(Newsfile Corp. - June 8, 2022) - Halberd Corporation (OTC Pink: HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd's patented extracorporeal disease eradication processes. Consistent with the press release of May 18, 2022, the Company has commenced its pursuits with mdi Consultants, Inc, an FDA application consulting firm, and the FDA to...
2022-06-08 8:00 AM EDT
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
Jackson Center, Pennsylvania--(Newsfile Corp. - May 24, 2022) - Halberd Corporation (OTC Pink: HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid. Several adverse health conditions are caused by excess quantities of particular components in blood or cerebral spinal fluid (CSF), such as proteins, cytokines, amino acids, etc. Elimination of excessive...
2022-05-24 8:00 AM EDT
Halberd Engages Professional Firm to Proceed with FDA Filings
Jackson Center, Pennsylvania--(Newsfile Corp. - May 18, 2022) - Halberd Corporation (OTC Pink: HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration's (FDA) complex application and certification processes. mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents and disclosures with the FDA in each stage of the process. After numerous discussions, Halberd is...
2022-05-18 8:00 AM EDT
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-List to OTCQB
Jackson Center, Pennsylvania--(Newsfile Corp. - May 12, 2022) - Halberd Corporation (OTC Pink: HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange. Once Halberd's shares are qualified under the Securities Exchange Act of 1934 (the "34 Act"), Halberd will become a fully reporting issuer pursuant to Section 12(g) of the '34 Act. The OTCQB index...
2022-05-12 8:00 AM EDT
Halberd CEO Letter
Jackson Center, Pennsylvania--(Newsfile Corp. - April 25, 2022) - Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB)This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team.Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases.Halberd demonstrated that its antigen elimination process is able to selectively eliminate target...
2022-04-25 8:00 AM EDT
Halberd Eliminates E. Coli in 20 Minutes Vs. 7-10 Days with Conventional Antibiotics
Jackson Center, Pennsylvania--(Newsfile Corp. - April 18, 2022) - Halberd Corporation (OTC PINK: HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This compares to up to 10 days using conventional antibiotic treatments as the current standard of...
2022-04-18 8:00 AM EDT
Halberd Entering the Medical Metaverse
Jackson Center, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Halberd Corporation (OTC PINK: HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT's) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc.Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in non-fungible tokens (NFT's) who can identify growth opportunities by monitoring...
2022-04-11 8:00 AM EDT
Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression
Jackson Center, Pennsylvania--(Newsfile Corp. - April 4, 2022) - Halberd Corporation (OTC Pink: HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to...
2022-04-04 8:00 AM EDT
Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
Jackson Center, Pennsylvania--(Newsfile Corp. - March 16, 2022) - Halberd Corporation (OTC Pink: HALB) announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and educator, to its team of technical experts and consultants. Dr. Durvasula will guide Halberd's...
2022-03-16 8:00 AM EDT
Halberd Expands Its Technical Expertise With the Addition of Microbiology Professor
Jackson Center, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Halberd Corporation (OTC PINK: HALB) is pleased to announce Youngstown State University's (YSU) Dr. Chester R. Cooper has joined its technical team. Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University. Dr. Cooper has been a valuable resource in Halberd's work at the university in the area of E. coli testing and analysis over the past several months.Dr. Cooper...
2022-03-08 8:00 AM EST
Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
Jackson Center, Pennsylvania--(Newsfile Corp. - March 1, 2022) - Halberd Corporation's (OTC Pink: HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown on the graph below.On the vertical axis is the Absorbance (a measure of binding...
2022-03-01 8:00 AM EST